Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
about
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and BeyondTrial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statementRole of noninvasive molecular imaging in determining responseThe Role of Melanoma Cell-Stroma Interaction in Cell Motility, Invasion, and Metastasis
P2860
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Patients with melanoma treated ...... dministration pooled analysis.
@en
Patients with melanoma treated ...... dministration pooled analysis.
@nl
type
label
Patients with melanoma treated ...... dministration pooled analysis.
@en
Patients with melanoma treated ...... dministration pooled analysis.
@nl
prefLabel
Patients with melanoma treated ...... dministration pooled analysis.
@en
Patients with melanoma treated ...... dministration pooled analysis.
@nl
P2093
P2860
P921
P1433
P1476
Patients with melanoma treated ...... dministration pooled analysis.
@en
P2093
Amy Barone
Dow-Chung Chi
Flora Mulkey
Gideon M Blumenthal
Huanyu Chen
Jennie Chang
Julia A Beaver
Kirsten B Goldberg
Maitreyee Hazarika
P2860
P304
P356
10.1016/S1470-2045(17)30846-X
P5008
P577
2018-01-17T00:00:00Z
2018-02-01T00:00:00Z